Caroline Germa

Company: Transcenta

Job title: Chief Medical Officer

Seminars:

Understanding the Synergistic Potential of Combining Claudin 18.2-Targeted Therapies with Immunotherapies 11:45 am

Examining the rationale for combining Claudin 18.2-targeted therapies with immunotherapies, such as checkpoint inhibitors, to enhance anti-tumor immune responses Exploring preclinical and clinical data supporting combination strategies, focusing on the synergistic effects and improved therapeutic outcomes Reviewing the impact of combination therapies on efficacy and safety profiles, including strategies to manage immune-related adverse eventsRead more

day: Conference Day 1